SetPoint Medical

SetPoint Medical is a privately held clinical-stage healthcare company founded in 2007. The company's slogan, "Regulating Inflammation - through the nervous system," reflects its dedication to treating patients with autoimmune diseases. SetPoint Medical operates within the Biotechnology and Health Care industries, and its headquarters is located in the United States. The company has recently secured an $80.00M Venture Round investment on 19 January 2023. The investment was led by a consortium of prominent investors, including New Enterprise Associates, Action Potential VC, Boston Scientific, Citta Ventures, Euclidean Capital, ShangBay Capital, SVE Capital, Gilmartin Capital LLC, and the Richard King Mellon Foundation. SetPoint Medical's focus is on developing a novel platform designed to stimulate the vagus nerve to activate innate anti-inflammatory pathways, thereby producing a systemic immune-restorative effect. This innovative technology offers a promising treatment alternative for conditions such as rheumatoid arthritis, inflammatory bowel disease, and other chronic autoimmune conditions. Importantly, the potential benefits of this platform include potentially less risk and cost than traditional drug therapy. In conclusion, SetPoint Medical's innovative approach to addressing autoimmune diseases, combined with its recent significant investment, positions the company as one to watch in the healthcare and biotechnology sectors.